Our mission is to accelerate the development of vaccines and immunotherapies against major global diseases by decoding how the human immune system fights disease.
The Human Vaccines Project and Vanderbilt University Medical Center launch a comprehensive study to determine new ways to provide long-lasting protection against influenza.
2018 Nobel Prize awarded for breakthroughs in harnessing the immune system against cancer. New York Times Letter calls for large-scale funding support to address fundamental gaps in our understanding of how our immune system prevents and controls disease.
The Human Vaccines Project welcome Seqirus as its latest partner. Seqirus, a CSL company, has been at the for forefront of influenza vaccine development and innovation for over a century.
The Human Vaccines Project and Vanderbilt University Medical Center will host a monthly Influenza Webinar Series, featuring prominent scientists discussing cutting-edge influenza research from laboratories around the world. The webinar series aims to foster scientific collaboration — a necessary component of progress toward a universal influenza vaccine. You can register for the series here.
The Michelson Prizes for Human Immunology and Vaccine Research have been awarded to three investigators applying disruptive research concepts to significantly advance the development of future vaccines and immunotherapies. Winners were selected via a rigorous, global competition and will be awarded $150,000 to fund specific aspects of their research.
Telethon Kids Institute in Australia has joined the Human Vaccines Project as its first international scientific hub, bringing significant health and scientific expertise in the areas of vaccines as well as working in pediatric and indigenous populations. The institute’s capacity will enhance the Project’s efforts toward better vaccines and immunotherapies, as well as work towards a universal flu vaccine.
The Human Vaccines Project welcomes Moncef Slaoui, PhD, to its Board of Directors. Dr. Slaoui served as Chairman of Global R&D at GSK, and was instrumental in the development HPV, pneumococcal and rotavirus vaccines. In 2016, he was recognized as one of Fortune Magazine’s “50 Greatest World Leaders” for his work on under-researched diseases that are common in the developing world.
Influenza vaccines are in the news, and a new approach is urgently needed. Here is a summary of recent press coverage around our new initiative on a universal influenza vaccine: The Wall Street Journal, Time Magazine / Bloomberg, MSN, Aspen Institute, STAT, Genome Web and CNBC.